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Abstract
Background:  Mucopolysaccharidoses (MPS) are inherited metabolic disorders caused by
mutations leading to dysfunction of one of enzymes involved in degradation of glycosaminoglycans
(GAGs). Due to their impaired degradation, GAGs accumulate in cells of patients, which results in
dysfunction of tissues and organs. Substrate reduction therapy is one of potential treatment of
these diseases. It was demonstrated previously that genistein (4', 5, 7-trihydroxyisoflavone) inhibits
synthesis and reduces levels of GAGs in cultures of fibroblasts of MPS patients. Recent pilot clinical
study indicated that such a therapy may be effective in MPS III (Sanfilippo syndrome).
Methods: To learn on details of the molecular mechanism of genistein-mediated inhibition of GAG
synthesis, efficiency of this process was studied by measuring of incorporation of labeled sulfate,
storage of GAGs in lysosomes was estimated by using electron microscopic techniques, and
efficiency of phosphorylation of epidermal growth factor (EGF) receptor was determined by using
an ELISA-based assay with fluorogenic substrates.
Results: Effects of genistein on inhibition of GAG synthesis and accumulation in fibroblasts from
patients suffering from various MPS types were abolished in the presence of an excess of EGF, and
were partially reversed by an increased concentration of genistein. No such effects were observed
when an excess of 17β-estradiol was used instead of EGF. Moreover, EGF-mediated stimulation of
phsophorylation of the EGF receptor was impaired in the presence of genistein in both wild-type
and MPS fibroblasts.
Conclusion:  The results presented in this report indicate that the mechanism of genistein-
mediated inhibition of GAG synthesis operates through epidermal growth factor (EGF)-dependent
pathway.
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Background
Mucopolysaccharidoses (MPS) are inherited metabolic
disorders, from the group of lysosomal storage diseases,
caused by mutations leading to dysfunction of one of
enzymes involved in degradation of glycosaminoglycans
(GAGs) (for reviews, see [1,2]). Due to their impaired deg-
radation, GAGs accumulate in cells of patients, which
results in dysfunction of tissues and organs, including the
heart, respiratory system, bones, joints and, in some cases,
central nervous system (CNS). The symptoms differ
between already described eleven types and subtypes of
MPS, which are distinguished biochemically on the basis
of the kind of accumulated GAG and the lacking enzyme.
Irrespective of the MPS type, the disease is usually fatal,
with average expected life span of one or two decades,
though severity and clinical progression of MPS vary sig-
nificantly between patients. These parameters are hardly
predictable, even when biochemical and genetic data is
available [3], though recent studies revealed a significant
progress in this matter [4,5].
Until recently, no effective, approved treatment was avail-
able for any MPS type. However, enzyme replacement
therapy (ERT), based on an intravenous infusion of an
active, recombinant form of a deficient enzyme, is cur-
rently used for treatment of patients suffering from MPS I,
MPS II and MPS VI [6-10]. This therapy is effective in treat-
ment of somatic symptoms, however, neurological symp-
toms developed due to GAGs accumulation in CNS
cannot be managed by ERT owing to an inefficient deliv-
ery of proteins through the blood-brain barrier (for
reviews, see [2,11]). The CNS dysfunction-related symp-
toms occur in some MPS I patients (subtype MPS IH),
most of MPS II and MPS VII patients, and all MPS III
patients [1], where they are especially severe.
Substrate reduction therapy is one of possible treatments
that could be effective in management of CNS-related
symptoms of MPS. If a small molecule, capable of cross-
ing the blood-brain barrier, was able to impair GAG syn-
thesis, it could be potentially employed to restore a
balance between GAG synthesis and degradation, which is
destroyed in cells of MPS patients due to inefficient break-
ing down of GAGs.
Rhodamine B, a small molecule causing inhibition of
GAG synthesis by an unknown mechanism, appeared to
be effective in reduction of GAG storage in somatic tissues
and in brain of MPS IIIA mice treated at the dose of 1 mg/
kg [12]. Moreover, improved behavior has been observed
in such mice [13]. On the other hand, the use of rhodam-
ine B in clinical practice is perhaps unlikely due to its pos-
sible toxic effects.
Another inhibitor of GAG synthesis is genistein, (4', 5, 7-
trihydroxyisoflavone or 5, 7-dihydroxy-3- (4-hydroxyphe-
nyl)-4H-1-benzopyran-4-one), a compound from the
group of isoflavones. A decreased production of GAGs
was observed in fibroblasts of MPS I, MPS II, MPS IIIA and
MPS IIIB patients, and a decrease in lysosomal GAG stor-
age was noted after incubation of the cells with genistein
at concentrations between 10 and 30 μM [14]. Further-
more, recent pilot clinical studies indicated that treatment
of patients suffering from MPS IIIA and MPS IIIB with a
genistein-rich isoflavone extract at the dose corresponding
to the amount of genistein equal to 5 mg/kg/day resulted
in statistically important improvement of all tested
parameters, including cognitive functions [15].
The results of the pilot clinical studies [15], as well as of
other studies on substrate reduction therapy in lysosomal
storage diseases, are encouraging [16]. However, to fully
explore a possibility of using genistein as a medicine for
treatment of MPS patients, the mechanism of its action
must be deciphered. The rationale of the use of genistein
in MPS was based on previous observations that maxi-
mum synthesis of some GAGs requires either follicle-
stimulating hormone or epidermal growth factor (EGF)
[17,18]. EGF influences expression of certain genes by
binding to its transmembrane receptor that upon interac-
tion becomes an active protein kinase, initiating a specific
kinase cascade that finally results in regulation of activity
of particular transcription factors [19]. This tyrosine-spe-
cific protein kinase activity of the EGF receptor is inhib-
ited by genistein [20,21]. Therefore, it was proposed to
call a potential substrate reduction therapy of MPS, which
is based on the action of genistein, 'gene-expression tar-
geted isoflavone therapy' (or GET IT) [14]. Nevertheless,
this name is still speculative, especially in the light of mul-
tiple biological activities of genistein, including its phy-
toestrogenic properties (for a recent review, see [22]).
Therefore, the aim of this work was to elucidate the basic
mechanism of genistein-mediated inhibition of GAG syn-
thesis, which results in correction of storage of these com-
pounds in lysosomes of cells from patients suffering from
MPS. Since MPS III (Sanfilippo syndrome) is the primary
MPS type for which GET IT is being developed, in our
studies we focused on this disease, though other MPS
types were also considered.
Methods
Fibroblasts and cell cultures
Skin fibroblast lines were either initiated from forearm
skin biopsies obtained from a healthy volunteer and MPS
II, MPS IIIA and MPS IIIB patients (diagnosed biochemi-
cally on the basis of determination of urinary GAG levels
and measurement of activities of particular enzymes in
plasma or leukocytes) or bought from Cascade Biologics
(Portland, OR, USA) (adult Human Dermal Fibroblasts;Journal of Biomedical Science 2009, 16:26 http://www.jbiomedsci.com/content/16/1/26
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HDFa). Cells were cultured to early confluence in 75 cm2
flasks in Dulbecco's Modiefied Eagle's Medium (DMEM)
supplemented with 10% heat inactivated Foetal Bovine
Serum (FBS) and Antibiotic Antimycotic Solution (AAS)
at 37°C in a humidified atmosphere of 5% (v/v) CO2.
Measurement of GAG synthesis
Fibroblasts were plated in 48-well plates and treated with
genistein at concentrations 10 and 30 μM (in DMSO
whose final concentration was 0.05%) either alone or in
combination with EGF (100 ng/ml) or 17β-estradiol (1
nM) in DMEM supplemented as described above. GAG
synthesis was monitored by measuring incorporation of
35S (from a radioactive sodium sulfate) into proteogly-
cans, according to Murata et al. [23]. Cells were labeled
with 20 μCi/ml of [35S]Na2SO4 for 24 h in the 50:50 mix-
ture of DMEM and growth medium lacking inorganic sul-
fate (Minimum Essential Medium Eagle- MEM),
supplemented with 2.5% FBS and AAS with appropriate
concentrations of additives sustained. After 24 h the
fibroblasts were washed six times with PBS and cultures
were subjected to papain digestion (0.03% papain in 0.1
M sodium acetate, pH 7.0) [24]. Aliquots of papain digest
were used for sulfate incorporation measurements in a
scintillation counter. For all experiments, unlabeled con-
trol samples were processed in parallel for the determina-
tion of DNA concentration. The pellet of fibroblasts
obtained after centrifugation of trypsinized cultures was
subjected to proteinase digestion, then diluted in TE
buffer (12–175 times depending on the intensity of the
response to PicoGreen dye) and analyzed according to the
protocol provided by the manufacturer of PicoGreen®
DNA Quantitation Reagent. GAG synthesis was calculated
per DNA amount.
Electron microscopic analysis of cells
Fibroblasts plated in 12-well plates were treated for 4 days
with genistein at concentrations 10 and 30 μM (in DMSO
whose final concentration was 0.05%) either alone or in
combination with EGF (100 ng/ml) or estradiol (1 nM) in
DMEM supplemented with 10% FBS and AAS. Before fix-
ation in 2.5% glutaraldehyde in 0.1 M PBS, the cultures
were washed 3 times with PBS. Transmission microscopy
studies were performed as described previously [25],
using Philips CM100 microscope.
Estimation of efficiency of phosphorylation of the EGF 
receptor
Efficiency of phosphorylation of the EGF receptor was
estimated by using an ELISA-based assay with fluorogenic
substrates to measure phosphorylated EGF receptor in the
context of a whole cell (Cell-Based ELISA: Human Phos-
pho-EGF R (Y1068) Immunoassay, R&D Systems Inc.,
Minneapolis, MN, USA), according to the manufacturer's
instruction. A specific and irreversible inhibitor of the EGF
receptor, 4- [(3-bromophenyl) amino]-6-acrylamido-
quinazoline, abbreviated as PD168393 (purchased from
Calbiochem, La Jolla, CA, USA), which acts by covalently
modifying cysteine-733, an amino acid located in the cat-
alytic domain of the ATP-binding pocket of the EGF recep-
tor, was used as a control inhibitor. The effect of short-
term (30 min) and long-term (24 h) exposure to genistein
at 10 and 30 μM or PD168393 at 10 and 30 nM, with or
without EGF (100 ng/ml), was examined.
Results
Genistein-mediated impairment of GAG synthesis
As demonstrated previously [14], addition of genistein to
cultures of fibroblasts results in impairment of synthesis
of GAGs; this was true also for the cell lines used in this
study, which derived from MPS IIIA (Fig. 1) and other
tested MPS patients (data not shown), and from a non-
MPS person (data not shown). As expected, the inhibition
of GAG synthesis, measured by incorporation of
[35S]SO4
2-, revealed the dose-response relationship as the
effect was more pronounced at 30 μM genistein than at 10
μM (Fig. 1 and results not shown).
Addition of EGF to the culture of MPS IIIA fibroblasts to
final concentration of 100 ng/ml resulted in an increase in
Effects of genistein, EGF, 17β-estradiol and combinations of  genistein with EGF or 17β-estradiol on GAG synthesis in  MPS IIIA fibroblasts Figure 1
Effects of genistein, EGF, 17β-estradiol and combina-
tions of genistein with EGF or 17β-estradiol on GAG 
synthesis in MPS IIIA fibroblasts. Cells were untreated 
(Ctrl) or treated with genistein at concentrations 10 or 30 
μM (G10 and G30, respectively) alone, EGF alone at 100 ng/
ml (EGF), 17β-estradiol alone at 1 nM (Est) or in following 
combinations: genistein (10 or 30 μM) with EGF (100 ng/ml) 
(EGF+G10 and EGF+G30, respectively) and genistein (10 or 
30 μM) with 17β-estradiol (1 nM) (Est+G10 and Est+G30, 
respectively). Cell cultures were labeled with 20 μCi/ml of 
[35S]Na2SO4 for 24 h, and GAG synthesis was monitored by 
measuring incorporation of 35S into proteoglycans. The 
results were calculated per DNA amount. The results are 
mean values of three experiments with error bars indicating 
SD.
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efficiency of GAG synthesis relative to untreated cells (Fig.
1). Little decrease in the level of GAG synthesis could be
observed by addition of genistein into this experimental
system to final concentration 10 μM. In the presence of
EGF, the inhibitory effect of genistein could be observed
only at 30 μM, although it was significantly less pro-
nounced than in the absence of EGF (Fig. 1). These results
indicate that there is an interplay between EGF and genis-
tein in the process of GAG synthesis regulation. Similar
results were obtained in experiments with other tested
MPS cell lines (data not shown).
No increase in GAG synthesis occurred in MPS IIIA cells in
the presence of 1 nM 17β-estradiol, and this compound
had also no significant effect on genistein-mediated
impairment of GAG production as decreased incorpora-
tion of 35S was observed even at low (10 μM) concentra-
tion of this isoflavone (Fig. 1). This suggests that the
estrogen-dependent pathways are not crucial in genistein-
mediated inhibition of GAG synthesis. Again, similar
results were obtained when other MPS fibroblasts were
tested (data not shown).
Genistein-mediated improvement of GAG storage
Effects of storage of GAGs can be visualized by electron
microscopic analysis of cultured cells. As expected, evi-
dent storage was observed in MPS IIIA fibroblasts, which
was not seen in normal cells (control fibroblasts from a
healthy person) (Fig. 2A and 2B). In the presence of gen-
istein, the storage was definitely decreased (Fig. 2C and
2D). However, addition of EGF to the MPS IIIA cell cul-
ture (to final concentration of 100 ng/ml) resulted in the
storage effects even more pronounced than in untreated
fibroblasts (Fig. 2E). This enhanced storage resulted in not
only a significantly increased number of intracellular lys-
osomes containing abnormal structures, but also in the
presence of some lysosomes with complex inclusions out-
side cells (Fig. 2E). Supplementation of the cultures with
genistein resulted in a partial alleviation of the EGF-medi-
ated effects (Fig. 2F and 2G). Results of experiments with
17β-estradiol (Fig. 2H, I and 2J) were roughly similar to
those obtained without any treatment of cell cultures and
when genistein was used alone. The electron microscopic
analysis could be quantified by counting the number of
complex storage structures (Table 1). In summary, the
results obtained in electron microscopic studies of fibrob-
lasts cultured in the presence of various compounds are
compatible with those obtained in experiments with
measurement of GAG synthesis, and support the conclu-
sion that genistein-mediated inhibition of GAG produc-
tion acts by influencing EGF-dependent process(es),
rather than those dependent on estrogen activities.
Effects of genistein on phosphorylation of the EGF 
receptor
The first step in the EGF-dependent signal transduction
pathway is autophosphorylation of the EGF receptor,
upon binding of EGF. Therefore, to test whether genistein
influences the EGF-mediated pathway, we have estimated
the kinase activity of the EGF receptor by measuring effi-
ciency of phosphorylation of this protein in the absence
and presence of EGF and/or genistein. Fibroblasts were
cultured in the standard medium, which in a short-term
experiment was followed by 30 min incubation with (or
without) genistein or a specific and irreversible tyrosine
kinase inhibitor (PD168393), and then by incubation
with 100 ng/ml of EGF for 5 min. In a long-term experi-
ment, fibroblasts were treated with the mixture of genis-
tein and EGF for 24 h.
As expected, we observed a significant increase in phos-
phorylation of the EGF receptor in the presence of 100 ng/
ml EGF in the culture of wild-type fibroblasts relative to
the non-stimulated culture (Figs. 3 and 4). The same phe-
nomenon (i.e. stimulation of the EGF receptor phosphor-
ylation by EGF) was detected in cultures of other tested
Table 1: Effects of genistein, EGF, 17β-estradiol and combinations of genistein with EGF or 17β-estradiol on accumulation of lysosomes 
containing complex storage structures in MPS IIIA fibroblasts
Cells Added agents a Average number of complex storage structures per 100 μm2
Genistein (μM) EGF (ng/ml) 17β-estradiol (nM)
Control 0 0 0 2
MPS IIIA 0 0 0 38
MPS IIIA 10 0 0 7
MPS IIIA 30 0 0 5
MPS IIIA 0 100 0 67
MPS IIIA 10 100 0 26
MPS IIIA 30 100 0 11
MPS IIIA 0 0 1 21
MPS IIIA 10 0 1 13
MPS IIIA 30 0 1 8
a Electron micrographs obtained as shown in Fig. 2 were analyzed by counting complex storage structures per 100 μm2.Journal of Biomedical Science 2009, 16:26 http://www.jbiomedsci.com/content/16/1/26
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fibroblasts, including those obtained from patients suffer-
ing from MPS (Fig. 3). The tyrosine kinase inhibitor
PD168393, used as a positive control, abolished this
phosphorylation stimulation (Fig. 3).
When fibroblasts were incubated with genistein together
with EGF or prior to addition of EGF, the phosphorylation
stimulation was reduced significantly, and the effect was
better pronounced at higher genistein concentration (30
μM) than at its lower concentration (10 μM). This was
true for both experimental systems (short-term and long-
term), although the efficiency of phosphorylation inhibi-
tion was generally more efficient when genistein was incu-
bated together with EGF for 24 h (Fig. 4) than if genistein
was added to the cell culture 30 min prior to addition of
EGF and further incubation for 5 min (Fig. 3). The
dependence of the phosphorylation efficiency on the
length of cell culture incubation with genistein is depicted
in Fig. 5, indicating that longer incubation resulted in
stronger inhibition of phosphorylation. Therefore, we
conclude that genistein affects the EGF-mediated signal
transduction pathway.
Discussion
Although the use of genistein in substrate reduction ther-
apy for mucopolysaccharidoses has been proposed on the
basis of inhibition of GAG synthesis and accumulation in
fibroblasts of MPS patients [14], and a pilot clinical study
revealed positive effects of the treatment with genistein-
rich isoflavone extract [15], the mechanism of regulation
Effects of genistein, EGF, 17β-estradiol and combinations of genistein with EGF or 17β-estradiol on accumulation of lysosomes  containing complex storage structures in MPS IIIAfibroblasts Figure 2
Effects of genistein, EGF, 17β-estradiol and combinations of genistein with EGF or 17β-estradiol on accumula-
tion of lysosomes containing complex storage structures in MPS IIIAfibroblasts. Control fibroblasts or MPS IIIA 
fibroblasts were untreated or treated for 4 days with genistein at concentrations 10 and 30 μM either alone or in combination 
with EGF (100 ng/ml) or 17β-estradiol (1 nM). Electron micrographs were performed at magnification 1650 x. Panels: (A), con-
trol (untreated wild-type cells); (B), untreated MPS IIIA cells; (C), MPS IIIA cells treated with 10 μM genistein; (D), MPS IIIA 
cells treated with 30 μM genistein; (E), MPS IIIA cells treated with 100 ng/ml EGF; (F), MPS IIIA cells treated with 100 ng/ml 
EGF and 10 μM genistein; (G), MPS IIIA cells treated with 100 ng/ml EGF and 30 μM genistein; (H), MPS IIIA cells treated with 
1 nM 17β-estradiol; (I), MPS IIIA cells treated with 1 nM 17β-estradiol and 10 μM genistein; (J), MPS IIIA cells treated with 1 nM 
17β-estradiol and 30 μM genistein.
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of GAG synthesis by genistein remained speculative. It
was assumed that genistein might regulate expression of
genes involved in GAG synthesis, and the therapy was
named "gene expression-targeted isoflavone therapy"
(GET IT). This assumption was based on previous find-
ings, which demonstrated an increased GAG synthesis in
the presence of EGF and inhibition of the kinase activity
of the EGF receptor by genistein [17,18,20]. Nevertheless,
since there are many biological activities of genistein [22],
this hypothesis had to be tested.
Results presented in this report confirmed that an excess
of EGF stimulates GAG synthesis, which is also true in
MPS fibroblasts, and indicated that under such conditions
accumulation of GAGs is more efficient than in untreated
patients' cells. In the latter case, the storage of abnormal
structures was so efficient that some lysosomes containing
complex undigested structures appeared outside cells. The
effects of EGF on GAG synthesis and storage could be par-
tially reversed only at relatively high concentration of gen-
istein (30 μM). Moreover, genistein reduced EGF-
mediated stimulation of autophosphorylation of the EGF
receptor, the first step in the EGF-dependent signal trans-
duction pathway. These results strongly suggest that
effects of genistein on GAG synthesis and accumulation in
MPS cells is due to inhibition of the kinase activity of the
EGF receptor and subsequent effects on expression of par-
ticular genes that are regulated through EGF-dependent
signal transduction. Therefore, it appears that the name
"gene expression-targeted isoflavone therapy" (GET IT) is
valid, indeed. Although genistein is a phytoestrogen, it
seems that this activity is not important in the process of
regulation of GAG synthesis by this isoflavone as no sig-
nificant effects on this process were observed in the pres-
ence of 17β-estradiol.
Despite a likely regulation of GAG synthesis by genistein
through negative control of EGF-dependent signal trans-
duction and expression of certain genes, we cannot
exclude other biological effects of this isoflavone, which
might contribute to observed positive effects during clini-
cal studies [15]. One of examples is an antioxidant activity
of genistein [26]. In this light, recent results which sig-
naled an involvement of the reactive oxygen species in the
Short-term effects of EGF and genistein on phosphorylation of the EGF receptor Figure 3
Short-term effects of EGF and genistein on phosphorylation of the EGF receptor. Fibroblasts were cultured in the 
absence of EGF, which indicated the residual phosphorylation level (baseline value), and in the presence of EGF (100 ng/ml for 
5 min) without any inhibitor (Ctrl) or with genistein (either 10 or 30 μM, marked as G10 or G30, respectively) or PD168393 
(either 10 or 30 nM, marked as Inh10 or Inh30, respectively) added 30 min before EGF. Results of experiments with HDFa 
(wild-type), MPS II and MPS IIIB cell (fibroblast) lines are shown. Other tested fibroblasts gave similar results (results not 
shown). The results were calculated as phospho-EGF receptor fluorescence at 600 nm normalized to the total EGF receptor 
fluorescence at 450 nm. Therefore, the obtained normalized values are in arbitrary units. Values represent mean ± range of 
duplicate determinations.
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genesis of neurodegeneration in MPS IIIB [27], may sug-
gest that genistein could have positive effects on neurolog-
ical and cognitive functions of MPS III patients (observed
in the clinical study [15]) also as an antioxidant. Thus,
although the primary mechanism of therapeutic effects of
genistein for MPS III patients appears to be modulation of
the EGF-dependent signal transduction, other genistein-
mediated processes should also be considered and inves-
tigated. Nevertheless, because of the encouraging results
of the pilot clinical study [15,16], no significant side
effects reported [15] and a good safety profile of the use of
genistein (revised and discussed recently [28]), the gene
expression-targeted isoflavone therapy (GET IT) remains a
hopeful potential treatment of patients suffering from
MPS III and perhaps also some other MPS types.
Conclusion
In this report we demonstrate that the mechanism of gen-
istein-mediated inhibition of GAG synthesis operates
through epidermal growth factor (EGF)-dependent path-
way. Therefore, since this pathway is involved in regula-
tion of gene expression, the therapy of
mucopolysaccharidosis based on this reaction can be
called 'Gene Expression-Targeted Isoflavone Therapy'
(GET IT).
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